Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Clinical trial NCT05219500 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05219500
- Sponsor
- Fusion Pharmaceuticals Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-16
- Primary completion
- 2025-05-30
- Enrollment
- 115
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.